Comparative Pharmacology
Head-to-head clinical analysis: AMJEVITA versus CYLTEZO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMJEVITA versus CYLTEZO.
AMJEVITA vs CYLTEZO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 10-20 days) in patients receiving 40 mg every other week. This long half-life supports biweekly dosing.
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Adalimumab (AMJEVITA) is eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No intact drug is excreted in urine. The Fe receptor-mediated recycling contributes to long half-life.
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor